R&D channel feed

Af­ter back-to-back tri­al flops, Realm slash­es its staff, halts re­search work and pon­ders a fire sale

7 years ago

As­traZeneca's res­pi­ra­to­ry group spells out some set­backs in its lat­est PhI­II read­out for GSK COPD ri­val PT010

7 years ago

Roche CEO Sev­erin Schwan is keep­ing his hand on the bud­get ax

7 years ago

Genen­tech team does some cut­ting-edge work on a new class of an­tibi­otics — here's why that's im­por­tant

7 years ago
Bioregnum
Opinion

Acor­da’s aw­ful, no good, just plain bad week gets worse as FDA hands ex­ecs an­oth­er de­lay on In­bri­ja — bat­tered shares tum­ble again

7 years ago

Vi­tal Ther­a­pies evis­cer­at­ed as PhI­II dis­as­ter forces it to dis­card sole as­set

7 years ago

Bris­tol-My­ers claims the lead in a race to de­vel­op a TYK2 drug, hop­ing to dis­rupt a huge mar­ket for an­ti-in­flam­ma­to­ries

7 years ago

Gilead, Gala­pa­gos re­port com­pet­i­tive num­bers for first big PhI­II read­out for fil­go­tinib in rheuma­toid arthri­tis

7 years ago

Mer­ck her­alds a rare Big Phar­ma suc­cess for an­tibi­ot­ic PhI­II, but it’s al­so a cau­tion­ary tale about the mar­ket

7 years ago
Pharma

Ham­mered hard by a sur­pris­ing FDA re­jec­tion, Io­n­is spin­out Akcea of­fers an ex­pla­na­tion and then chops 1-in-10 staffers

7 years ago
Pharma

Zealand hands off dis­ap­point­ing di­a­betes rev­enue from Sanofi in ex­change for a $205M in­jec­tion to back a new pipeline

7 years ago

Atara brings an­oth­er ex­pe­ri­enced in­ves­ti­ga­tor on­to its off-the-shelf CAR-T quest in lat­est col­lab­o­ra­tion

7 years ago
Discovery

Gilead, Gala­pa­gos clear an­oth­er PhII hur­dle for fil­go­tinib, but can they hope to catch up with No­var­tis’ Cosen­tyx?

7 years ago

A new CAR-T is cred­it­ed with a 'sur­pris­ing' im­pact in tiny study of ad­vanced liv­er can­cer — rais­ing hopes on sol­id tu­mors

7 years ago

Li­cens­ing As­traZeneca castoff, Bio­haven preps PhI­II ef­fort in new neu­rode­gen­er­a­tive in­di­ca­tion

7 years ago
Pharma

Sang­amo team rush­es to de­fend first hu­man gene edit­ing da­ta as MPS II ther­a­py of­fers a hit — and a miss

7 years ago

Once a block­buster-to-be, Te­va fi­nal­ly sounds taps for its PhI­II los­er laquin­i­mod

7 years ago
Pharma

New re­port re-ig­nites fresh buzz that Bay­er is prep­ping an R&D over­haul and job cuts

7 years ago

The high-roller club in bio­phar­ma: Who’s pay­ing top-dol­lar for up­fronts? And who are the busiest play­ers at the deal ta­ble?

7 years ago
Pharma

In lat­est set­back, As­traZeneca’s high hopes for its lu­pus drug an­i­frol­um­ab crushed by a PhI­II fail­ure

7 years ago

Pfiz­er ax­es a key Duchenne MD pro­gram af­ter PhII flop, rais­ing new doubts for a drug cat­e­go­ry that at­tract­ed Roche and Bio­gen

7 years ago

A faster treat­ment for tu­ber­cu­lo­sis? TB Al­liance launch­es piv­otal tri­al for four-drug reg­i­men

7 years ago
Discovery

A for­mer fail­ure in PhII, the go-go FDA says it’s ready to con­sid­er an ac­cel­er­at­ed short­cut for Ul­tragenyx's UX007

7 years ago

Sophiris says it’s ready to get back on track with lead drug af­ter pa­tient death — but ques­tions linger

7 years ago
First page Previous page 263264265266267268269 Next page Last page
A service from the Financial Times